Investor Relations

BrainsWay is dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology is Deep-TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment.

BrainsWay Therapy’s technology is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for Deep TMS technology.

BrainsWay’s treatment is FDA cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288).

The company’s proprietary technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held across the globe.

For more information please contact:

Mr. Hadar Levy, CFO

Office Tel +972-(0)2-647-6010

Mobile +972-(0)54-5699133

Fax +972-(0)2-581-2517

US: +1-844-3867-001  or 1-844-DTMS-001